RX.V BIOYF Between Cysview and this new product and continued growth in other products the 2nd half of this year the growth will be up big I think. No to mention the relaunch of that product they had to recall. So basically they're going from 5 to 8 products.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.